• Search
  • Helpdesk
  • Sales contact

Kayentis announces the creation of its strategic committee

17 November 2015

Four leading figures in Life Sciences have accepted director Guillaume Juge’s invitation to join the body and they are Pr Patrizia Paterlini-Brechot, Pierre-Olivier Goineau, Pr Ronan Roussel and Pr Stephen Senn. All have been chosen for their expertise in how to deal with clinical trials and their regulatory issues and their leaning towards technological solutions.

For Guillaume Juge, “the main aim of this strategic committee is to help Kayentis develop its product offering and roadmap. Members will also be given the opportunity to contribute to the international development of a French CRO (clinical research organization).

About the members of the strategic committee

  • Pr Patrizia Paterlini-Bréchot: Professor of Cellular Biology and Oncology at the Necker-Enfants malades Faculty of Medecine in Paris. Inventor of the ISET test (Isolation by Size of Epithelial Tumor cells), a non-invasive diagnostic method for solid cancers.
  • Pierre-Olivier Goineau: co-founder of Erytech pharma. President of Goineau Development & Finance and France Biotech.
  • Pr Ronan Roussel: Professor of Diabetology and Endocrinology at the Bichat-Claude Bernard hospital and the Cordeliers Research Centre.
  • Stephen Senn: Professor of Statistics and a specialist in clinical research methodology. Head of Unit at the Luxembourg Institute of Health’s “research methodology and statistics” competence centre.

Guillaume JUGE, CEO – Kayentis

Follow us on social media
Subscribe to our newsletter
About the author
Meet us at the following events

Mobile in Clinical Trials

16 SEPT 2024 • Philadelphia, USA

DPharm 2024

17-18 SEPT 2024 • Philadelphia, USA

SCDM 2024

29 SEPT - 2 OCT 2024 • Boston, USA


13-16 OCT 2024 • Cologne, Germany


10-13 NOV 2024 • Cologne, Germany

DMB 2024

13 NOV 2024 • Paris, France

SCOPE 2025

FEB 3-6 2025 • Orlando, USA
Booth #931 https://www.scopesummit.com/